Overview

RD13-01 for Patients With r/r CD7+ T-ALL/T-LBL

Status:
Recruiting
Trial end date:
2022-11-15
Target enrollment:
Participant gender:
Summary
This study is designed to explore the safety of RD13-01 for patients with CD7+ relapsed and/or refractory T cell acute lymphoblastic leukemia or lymphoblastic lymphoma. And to evaluate the efficacy and pharmacokinetics of RD13-01 in patients.
Phase:
N/A
Details
Lead Sponsor:
Min Xiang